1. Home
  2. YHGJ vs LYRA Comparison

YHGJ vs LYRA Comparison

Compare YHGJ & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Yunhong Green CTI Ltd.

YHGJ

Yunhong Green CTI Ltd.

N/A

Current Price

$4.18

Market Cap

12.3M

Sector

Industrials

ML Signal

N/A

Logo Lyra Therapeutics Inc.

LYRA

Lyra Therapeutics Inc.

HOLD

Current Price

$3.76

Market Cap

7.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YHGJ
LYRA
Founded
1975
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Chemicals
Medical/Dental Instruments
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.3M
7.6M
IPO Year
1997
2020

Fundamental Metrics

Financial Performance
Metric
YHGJ
LYRA
Price
$4.18
$3.76
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$16.00
AVG Volume (30 Days)
16.7K
92.2K
Earning Date
11-13-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$19,377,000.00
$600,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$93.90
P/E Ratio
N/A
N/A
Revenue Growth
4.41
N/A
52 Week Low
$4.00
$2.84
52 Week High
$12.70
$37.50

Technical Indicators

Market Signals
Indicator
YHGJ
LYRA
Relative Strength Index (RSI) 40.07 39.75
Support Level $4.08 $3.55
Resistance Level $5.43 $4.25
Average True Range (ATR) 0.35 0.42
MACD -0.07 0.06
Stochastic Oscillator 17.38 13.39

Price Performance

Historical Comparison
YHGJ
LYRA

About YHGJ Yunhong Green CTI Ltd.

Yunhong Green CTI Ltd manufactures and marketers of foil balloons and produces laminated and printed films for commercial uses. The company also distributes balloon-inspired and other gift items, and continues development of compostable material solutions, and markets its products throughout the United States and in several other countries.

About LYRA Lyra Therapeutics Inc.

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

Share on Social Networks: